Based on that PKM2 acts as an oncogene and Bim plays a role of tumor suppressor in HCC, it is not surprising to find that patients with high PKM2 and low Bim expression should be more clinically followed up. The gene discussed is BCL2L11; the disease is hepatocellular carcinoma.